Core Viewpoint - Jingtai Holdings (02228) has seen a significant increase in stock price, rising over 8% in early trading, attributed to a strategic partnership with Mirxes for early cancer screening and drug development [1] Group 1: Company Developments - Jingtai Holdings' stock price rose by 6.98% to HKD 10.12, with a trading volume of HKD 129 million [1] - The collaboration with Mirxes aims to integrate strengths in early detection and drug development, focusing on a "diagnosis and treatment integration" solution for prevalent cancers in Asia [1] Group 2: Research and Analysis - Shenwan Hongyuan released a report highlighting Jingtai Holdings' core technology in "physical computing + AI + robotics," establishing a complete closed loop for early drug development from algorithms to automated laboratories [1] - The company's business has expanded from AI drug development to a broader "AI4S" platform, showcasing the potential for technology transfer to new materials and demonstrating significant technological breadth and platform value [1] - The initial coverage of Jingtai Holdings has been rated as "Buy" by analysts [1]
晶泰控股(02228)早盘涨超8% 公司业务已实现从AI制药到AI4S平台延伸